American Association for Cancer Research

Molecularly Targeted Therapies: Mechanisms of Resistance

Bookmark and Share

 

Molecularly Targeted Therapies: Mechanisms of Resistance 2012Molecularly Targeted Therapies:
Mechanisms of Resistance

May 9-12, 2012
The Westin San Diego
San Diego, CA
Abstract submission deadline: Monday, February 27
Advance registration deadline: Monday, April 2

CONFERENCE CO-CHAIRPERSONS:
Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA
Mace L. Rothenberg, Pfizer, New York, NY

This exciting conference will address the question of how certain proliferating cells fail to respond to certain therapies and will explore the biologic and genetic causes for variations in tumor behavior. Researchers from academia, government and industry are encouraged to attend and contribute to this important exchange to further our understanding of cancer drug resistance and the implications for new treatments.

 

MAJOR SUPPORTER

Eli Lilly and Company

 

Genentech - A Member of the Roche Group



SUPPORTERS


Amgen


Bristol-Myers Squibb


Celgene


Gilead



AWARD SUPPORTERS


Aflac, Inc.


NCI Center to Reduce Cancer Health Disparities